Final draft guidance finds benefits of 2 Alzheimer’s treatments remain too small to justify the additional costs to the NHS The benefits of Alzheimer’s treatments donanemab and lecanemab remain too small to justify the additional costs

#NICE #NICEFAD #NICEfinaldraftguidance #Alzheimerstreatments #NHS #donanemab #Kisunla #EliLilly #lecanemab #Leqembi #Eisai #negativedraftrecommendations #mildcognitiveimpairment #milddementia #Alzheimersdisease #NHSresources #NICEassessments #cognitiveimpairment
www.nice.org.uk/news/article...

Leqembi approved as first treatment to slow early Alzheimer’s progression - PharmaTimes European Commission grants authorisation for Eisai and Biogen therapy

#neurology #Leqembi #lecanemab #Alzheimerstreatment #Eisai #Biogen #earlyAlzheimersdisease #mildcognitiveimpairment #milddementia #Alzheimers #apolipoproteinEε4noncarriers #amyloidpathology #ClarityADtrial #amyloidbetaprotofibrils #cognitivedecline
pharmatimes.com/news/leqembi...